Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Sr. VP, Business Development | February 28, 2017 | March 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date February 28, 2017 · Filed March 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,985 |
Reported balance
After 2017-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-28 · Grant · Acquired 12,500 · Balance 28,985 |
| Common StockSEC Table I · non-derivative | Direct | 23,919 |
Reported balance
After 2017-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-02-28 · Tax withholding · Disposed 5,066 · Balance 23,919 |
| Common StockSEC Table I · non-derivative | Direct | 43,919 |
Reported balance
After 2017-02-28 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-02-28 · Grant · Acquired 20,000 · Balance 43,919 F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2027-02-28 | Direct | 8,823 |
Reported balance
After 2017-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-28 · Grant · Acquired 8,823 · Balance 8,823 F2: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2027-02-28 | Direct | 11,177 |
Reported balance
After 2017-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-28 · Grant · Acquired 11,177 · Balance 11,177 F2: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020.
F2: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,177 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · derivative · entry 5 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,177 Underlying: Common Stock · 11,177 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 8,823 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · derivative · entry 4 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,823 Underlying: Common Stock · 8,823 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 3 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,919 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 5,066 | $10.60 | $53,699.60 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 2 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,919 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 12,500 | $0.00 | $12.50 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 1 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,985 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.